- Home
- ZH vs CNTX Comparison
ZH vs CNTX Comparison
Compare ZH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZH | CNTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.7M | 283.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZH | CNTX |
|---|---|---|
| Price | $2.75 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 389.0K | ★ 947.7K |
| Earning Date | 03-25-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $0.49 |
| 52 Week High | $5.55 | $3.62 |
Technical Indicators
Market Signals| Indicator | ZH | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 46.14 |
| Support Level | N/A | $2.07 |
| Resistance Level | $4.53 | $2.72 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 27.78 | 7.02 |
Price Performance
Historical ComparisonAbout ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.